pT3N0期乳腺癌全乳腺切除术后辅助放疗价值探讨
被引量:1
摘要
术后辅助放疗对腋窝淋巴结阳性的乳腺癌可降低局部复发率进而生存获益”^[1-3],但对腋窝淋巴结阴性的原发肿瘤>5cm(这PT3N0期)的乳腺癌全乳腺切除术后患者,是否放疗一直存在着争议。笔者通过对53例未行术后辅助放疗的PT3N0期乳腺癌全乳腺切除术后患者的临床资料进行回顾分析,探讨术后辅助放疗的价值。一、材料与方法1.入组标准:女性,单侧乳腺癌,行全乳腺切除术和腋窝淋巴结清扫术;
出处
《中华放射肿瘤学杂志》
CSCD
北大核心
2012年第5期415-416,共2页
Chinese Journal of Radiation Oncology
基金
广东省科技计划社会发展项目(20088060600019)
参考文献7
-
1Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med, 1997,337:949-955.
-
2Overgaard M, .]ensen MB, Overgaard J, et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen : Danish Breast Cancer Cooperative Group DBCG 82c randomised triM. Lancet, 1999,353 : 1641-1648.
-
3Ragaz J, Olivotto IA, Spinelli JJ, et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial..1 Natl Cancer Inst .2005.97 : 116-126.
-
4Floyd SR, Taghian AG. Post-mastectomy radiation in large node- negative breast tumors: does size really matter? Radiother Oncol, 2009,91:33-37.
-
5HelintO M, Blomqvist C, Heikkilo P, et al. Post-mastectomy radiotherapy in pT3 No Mo breast cancer: is it neededi Radiother Oncol, 1999,52:213-217.
-
6Taghian AG, Jeong JH, Mamounas EP, et al. Low locoregional recurrence rate among node-negative breast cancer patients with tumors 5 cm or larger treated by mastectomy, with or without adjuvant systemic therapy and without radiotherapy: results from five national surgical adjuvant breast and bowel project randomized clinical trials. J Clin 0ncol,2006,24:3927-3932.
-
7Early breast cancer trialists' collaborative group (EBCTCG). Comparisons between different poly chemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100000 women in 123 randomised trials. Lancet, 2012,379 : 432- 444.
同被引文献19
-
1邢松丽,刘凯,罗小光,等.刮痧和中药对乳腺增生病大鼠病理形态、血清性激素的影响和作用机制[c].2011年全国中医美容学术年会暨贵州省医学美学与美容学、激光医学分会学术年会论文集.2011:14-18.
-
2Bjerrome Ahlin H, Ktilby L, Elander A, et al. Improved results after implementation of the Ghent algorithm for subcutaneous mastectomy in female-to-male transsexuals [J]. J Plast Surg Hand Surg, 2014, 3 (11): 55-57.
-
3Romics L Jr, Stallard S, Weiler-Mithoff E. Oncologic safety of skin-sparing mastectomy followed by immediate breast reconstruction:rate and localization of recurrences, and impact of reconstruction techniques[J]. Orv Hetil, 2013, 154(5): 163-171.
-
4Stolier A J, Levine EA. Reducing the risk of nipple necrosis:technical observations in 340 nipple-sparing mastectomies [J]. Breast J, 2013, 19(2): 173-179.
-
5Yang Y, Sun J. Subcutaneous mastectomy for juvenile mammary hypertrophy:a clinical experience[J]. Breast J, 2013, 19(6): 689-690.
-
6Ferraro GA, Romano T, De Francesco F, et al. Management of prepubertal gynecomastia in two monozygotic twins with Peutz-Jeghers syndrome: from aromatase inhibitors to subcutaneous mastectomy[J].Aesthetic Plast Surg, 2013, 37(5): 1012-1022.
-
7Cao H, Yang ZX, Sun YH, et al. Endoscopic subcutaneous mastectomy: A novel and effective treatment for gynecomastia [J]. Exp Ther Med, 2013, 5(6): 1683-1686.
-
8Irwin GW, Black A, Refsum SE, et al. Skin-reducing mastectomy and one-stage implant reconstruction with a myodermal flap: a safe and effective technique in risk-reducing and therapeutic mastectomy[J]. J Plast Reconstr Aesthet Surg, 2013, 66(9): 1188-1194.
-
9Vrekoussis T, Perabo M, Himsl I, et al. Bilateral prophylactic skin-reducing nipple-sparing masteetomy with immediate breast reconstruction using only a vascularized dermal-subcutaneous pediele:teehnique and possible advantages [J]. Arch Gynecol Obstet, 2013, 287(4): 749-753.
-
10Cregten-Escobar P, Bouman MB, Buncamper ME, et al. Subcutaneous mastectomy in female-to-male transsexuals:a retrospective cohort- analysis of 202 patients[J]. J Sex Med, 2012, 9(12): 3148-3153.
二级引证文献15
-
1杨更午,段玉然,张世耀,邵慧平,陈桂霞,张建平.2种方法治疗乳腺增生伴癌症的临床效果对比观察[J].临床合理用药杂志,2015,8(28):135-137. 被引量:5
-
2王永德,郑洪,孙高.对比研究不同治疗方法对乳腺增生患者预后的影响[J].今日健康,2015,14(10):85-85.
-
3杨更午,段玉然,张世耀,邵慧平,陈桂霞,张建平.Notch1与CyclinD1的表达与切除术治疗乳腺增生伴癌变疗效的相关性分析[J].临床合理用药杂志,2015,8(34):159-161. 被引量:1
-
4赵冬来.皮下全乳腺切除术治疗乳腺囊性增生临床效果评价[J].中国继续医学教育,2016,8(5):108-109. 被引量:7
-
5乔海军.保乳手术和改良根治术对乳腺癌患者治疗效果对比分析[J].中国实用医刊,2016,43(7):104-105. 被引量:14
-
6康迪.皮下乳腺切除术治疗严重乳腺增生症87例临床疗效分析[J].实用临床医药杂志,2016,20(13):97-98. 被引量:10
-
7尹义学.皮下乳腺切除术治疗乳腺增生的效果研讨[J].当代医药论丛,2018,16(11):46-47. 被引量:4
-
8倪浩.皮下乳腺切除术治疗乳腺增生伴癌症的临床疗效观察[J].大医生,2017,2(Z2):215-215. 被引量:1
-
9古丽旦.哈山.分析皮下全乳腺切除术治疗重症乳腺增生的临床疗效[J].世界最新医学信息文摘,2018,18(18):125-125. 被引量:1
-
10聂程亮.皮下全乳腺切除术治疗重症乳腺增生的临床效果研究[J].基层医学论坛,2019,23(5):610-612. 被引量:4
-
1戴明明,吴三纲,何振宇,林勤,李凤岩,管迅行.Ki-67对腋窝淋巴结阳性的乳腺癌全乳腺切除术后的预后价值[J].现代肿瘤医学,2013,21(7):1503-1507. 被引量:3
-
2王显,王清欣,姚萍,赵湘兰,布洁,郭汝元,彭一香,赵湘萍,彭桂香.乳腺癌的治疗(附33例分析)[J].山西职工医学院学报,1994,4(3):7-9.
-
3张勇,周进英,李江丽.放疗在乳腺癌综合治疗中的作用[J].中国现代药物应用,2013,7(18):81-81. 被引量:4
-
4陈坚贤,黄广优,黄升武,蒙以良,吴三纲.不同国家和组织乳腺癌全乳腺切除术后辅助放疗指南的差异[J].现代肿瘤医学,2015,23(24):3609-3613. 被引量:5
-
5郑伟刚,宋强,华春生.乳腺分叶状肿瘤5例报告[J].山东医药,2010,50(34):69-69.
-
6辛智芳,王志惠,姚曙光.乳腺肉瘤34例分析[J].中国肿瘤临床,2002,29(12):877-880. 被引量:10
-
7吴斌.乳腺肉瘤50例临床分析[J].山东医药,2007,47(9):42-43. 被引量:5
-
8刘秀芹.乳腺癌145例围术期护理[J].齐鲁护理杂志(下半月刊)(外科护理),2008,14(2):50-51. 被引量:8
-
9白剑,严志登,刘学强,李建明,杨家恒,万恒荣.乳腔镜下前哨淋巴结活检和腋窝淋巴结清扫术的临床研究(附36例报告)[J].中国医师进修杂志(外科版),2006,29(8):21-23. 被引量:2
-
10陈勇.Ki-67在乳腺癌全乳腺切除术后预后分析中的价值[J].中外医学研究,2017,15(3):12-13.